Find Academic Supervisors

• Leishmaniasis
• Immunology
• Parasitology
• +3 more

Deborah Frances Smith is a Professor affiliated with the Centre for Immunology and Infection. She has held former roles including Head Of Department, Biology Pro-Vice-Chancellor for Research, and Special Adviser to the Vice Chancellor in the Vice Chancellor's Office. She is also associated with CNAP (Cancer and Neuroscience Academic Programme) and the Jack Birch Unit. Her research focuses on leishmaniasis, parasite biology, and drug/vaccine development. Key projects include leading the 'C2D2 research 1a & 2b' (2012–2012) to establish sandfly colonies for leishmaniasis studies and co-investigating an integrated crystallization facility (2013–2018). She secured the Wolfson Research merit Award (2009–2010) from the Royal Society. Her work spans academic leadership, collaborative research, and translational medicine targeting neglected tropical diseases.

Ahmet TUTARView profile

Professor

• Organic Chemistry
• Photochemistry
• Bromination Reactions
• +3 more

Prof. Dr. Ahmet Tutar is a faculty member in the Department of Chemistry at Sakarya University . His academic activities include teaching courses such as Organic Chemistry I/II , Organic Synthesis Design , and Stereochemistry , alongside supervising numerous master's theses in organic synthesis and humic substance applications. Research Interests: Focus on bromination reactions , BODIPY dye synthesis , humic/fulvic acid characterization , computational chemistry , and pharmaceutical applications of organic compounds. Key Article Trends: Recent publications emphasize photobromination methods , metal-organic frameworks , and biological activity of brominated derivatives , with keywords spanning organic synthesis , biochemistry , and environmental chemistry . Thesis Supervision: Guided 35+ master's theses (2007-2013) on topics like synthesis of brominated indan derivatives , humic acid extraction , and photobromination of terpenes .

Rainer HaagView profile

Professor

• Biodegradable Materials
• Sustainable Polymer Chemistry
• Dynamic Hydrogels
• +7 more

Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.

Vadim CherezovView profile

Professor

• Membrane Protein Structure and Function
• G Protein-Coupled Receptors (GPCRs)
• Lipid-Protein Interactions
• +3 more

Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.

Steven G. ClarkeView profile

Professor

• Biochemistry
• Systems Biology
• Biological Regulation
• +8 more

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

David VocadloView profile

Professor

• Bioorganic Chemistry
• Chemical Biology
• Glycobiology
• +3 more

David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.

• Proteasome Research
• Structural Biology
• Enzyme Mechanisms
• +2 more

Michael Groll serves as Professor and Chair of Biochemistry at the Technical University of Munich (TUM), where he leads structural biology and enzymology research with a focus on proteasome mechanisms and inhibitor development. His laboratory, located at the Ernst-Otto-Fischer-Str. 8 campus in Garching, maintains active collaborations in drug discovery for cancer and infectious diseases. His primary research domains include proteasome inhibition, enzyme catalysis, and natural product biosynthesis, employing X-ray crystallography, biochemical assays, and bioengineering to dissect molecular mechanisms. Recent work emphasizes AI-guided enzyme optimization, bacterial stress response targeting, and structural characterization of halogenation enzymes, reflecting interdisciplinary approaches bridging chemistry and biology. Analysis of his 2023-2025 publications reveals consistent innovation in proteasome-targeted therapeutics, with 15 high-impact papers featuring structural insights into enzyme-inhibitor complexes and biosynthetic pathways. Key trends include engineering megasynthetases for immunoproteasome inhibitors, optical control of protein degradation, and elucidating metal-dependent mechanisms in antibiotic biosynthesis. No scientific awards were documented in the provided source material. While specific grant details and student mentorship records were not disclosed, his extensive publication record indicates leadership in collaborative research projects involving structural biology and chemical biology methodologies. The Chair of Biochemistry under Prof. Groll operates as a hub for structural enzymology, housing facilities for protein crystallography, enzyme kinetics, and natural product characterization. His team actively contributes to TUM's research ecosystem through partnerships with pharmaceutical groups and international structural biology consortia.

John A. Copland, IIIView profile

Professor

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +3 more

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

Brian HieView profile

Assistant Professor

• Machine Learning
• Computational Biology
• Protein Engineering
• +6 more

Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .

Megan L. MatthewsView profile

Assistant Professor

• Chemical Biology
• Enzymology
• Chemical Proteomics
• +7 more

Megan L. Matthews is an Assistant Professor in the Department of Chemistry at the University of Pennsylvania, School of Arts & Sciences, where she leads an active research group focused on chemical biology and enzymology. Her lab develops innovative chemical proteomics technologies to uncover novel enzyme cofactors and regulatory post-translational modifications, particularly those involving reactive electrophiles, which cannot be predicted from genomic sequences. B.S. in Chemistry, Miami University (2005) Ph.D. in Chemistry, The Pennsylvania State University (2011) Postdoctoral Fellow, The Scripps Research Institute (2012–2017) Her research centers on the concept of the 'electrophilome'—a largely unexplored half of the reactive proteome. By designing 'reverse-polarity' chemical probes, her group enables the discovery of functionally significant electrophilic modifications in proteins, especially those involved in cancer and Alzheimer’s disease. These discoveries open new avenues for therapeutic intervention through covalent targeting. The recent publications demonstrate a consistent focus on enzyme mechanisms, cofactor discovery, and chemical probe development. Her work spans from fundamental enzymology (e.g., halogenases, ribonucleotide reductases) to applied chemical biology (e.g., hydrazine probes, chemoproteomic profiling). The keywords across her publications highlight emerging themes in metalloenzymes, radical chemistry, and covalent proteome mapping. Her scientific contributions have been recognized through prestigious fellowships, including the Merck Helen Hay Whitney Postdoctoral Fellowship. She has published in top-tier journals such as Nature , Nature Chemical Biology , and Journal of the American Chemical Society . Dr. Matthews advises graduate students and postdoctoral researchers in her lab, fostering a collaborative and inclusive environment. Her lab emphasizes the importance of diverse perspectives in scientific discovery. She has secured research funding to support projects in probe development, target characterization, and disease mechanism studies, particularly in neurodegenerative diseases and cancer. The Matthews Lab is actively engaged in advancing reverse-polarity activity-based protein profiling (RP-ABPP) for in vivo applications and inhibitor screening. The group collaborates with experts in structural biology, spectroscopy, and disease modeling to translate basic discoveries into therapeutic insights.

Thomas LectkaView profile

Professor

• Organic Chemistry
• Synthetic Chemistry
• Physical Organic Chemistry
• +3 more

Thomas Lectka is the Jean and Norman Scowe Professor in the Department of Chemistry at Johns Hopkins University, where he has been a faculty member since 1994. His research focuses on synthetic and physical organic chemistry, particularly in the area of organofluorine chemistry. PhD, Cornell University Postdoctoral Fellow, Heidelberg (Alexander von Humboldt Fellow) Postdoctoral Fellow, Harvard University (NIH Fellow) Dr. Lectka's research is centered on developing novel synthetic methods, especially for fluorination, and understanding the physical organic principles underlying reactivity. His work spans radical fluorination , catalytic asymmetric synthesis , and the design of fluorinated bioactive molecules . Using a combination of experimental and computational techniques, his lab investigates C-F bond formation , reaction mechanisms , and the biological applications of fluorinated compounds. His recent work, as reflected in publications from 2010 to 2024, shows a consistent trajectory in advancing fluorination methodologies, with increasing emphasis on site-selectivity , enantiocontrol , and biomedical relevance . Themes include the development of new reagents, mechanistic studies, and the synthesis of fluorinated natural product analogs and peptidomimetics. Dr. Lectka has received numerous honors and awards, including: ACS Arthur C. Cope Scholar (2024) ACS Maryland Chemist of the Year (2017) John Simon Guggenheim Memorial Fellowship Dreyfus Teacher-Scholar Award Sloan Fellowship NSF CAREER Award NIH First Award Eli Lilly Grantee Award He actively mentors graduate and undergraduate students in his research group, contributing to education and training in organic chemistry. His lab, The Lectka Group , is supported by grants from the NIH and NSF, enabling cutting-edge research in synthetic methodology and physical organic studies. The group fosters a collaborative environment focused on innovation in fluorine chemistry. The Lectka Group is an active research laboratory at Johns Hopkins University dedicated to pushing the boundaries of synthetic organic chemistry through the exploration of fluorine's unique properties. Current projects include site-selective radical fluorination and the synthesis of unusual fluorinated species, aiming to provide new tools for drug discovery and materials science.

Brent PageView profile

Associate Professor

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +13 more

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

Jacques ArchambaultView profile

Professor

• Human Papillomavirus (HPV)
• Polyomavirus
• Viral DNA Replication
• +4 more

Dr. Jacques Archambault is a Professor in the Department of Microbiology and Immunology at McGill University , and an associate member of the Division of Experimental Medicine since 2016. His research focuses on the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), with an emphasis on their replication mechanisms as episomes in host cells. The Archambault laboratory employs functional genomics, proteomics, and chemical biology approaches to identify cellular pathways exploited by these viruses and develop high-throughput assays for screening small molecule inhibitors of viral replication. Analysis of his recent publications reveals a strong focus on HPV and HPyV replication machinery, including studies on the E1 helicase, UAF1-USP1 interactions, and structural characterization of viral proteins involved in DNA replication. His work bridges virology, oncology, and drug discovery, particularly targeting oncogenic HPV types implicated in anogenital and oropharyngeal cancers, as well as HPyVs like BKPyV and JCPyV that cause pathologies in immunosuppressed patients. Current efforts in the lab aim to elucidate the molecular mechanisms by which HPVs and HPyVs replicate their genomes and to develop antiviral therapies targeting these processes. Techniques such as fluorescence anisotropy, NMR spectroscopy, and crystallography are frequently employed to study protein-DNA and protein-protein interactions critical to viral replication.

Xi ChenView profile

Professor

• Carbohydrate Chemistry
• Glycobiology
• Enzymology
• +7 more

Dr. Xi Chen is a Professor in the Department of Chemistry at the University of California, Davis, where he has been a faculty member since 2003. His research spans carbohydrate chemistry, glycobiology, and cancer biology, with notable contributions to chemoenzymatic methods for glycoconjugate synthesis. Dr. Chen's work focuses on developing hybrid chemical-enzymatic approaches to synthesize complex carbohydrates and glycoconjugates, characterizing glycosyltransferase mechanisms, and designing enzyme mutants for improved catalysis. He also investigates carbohydrate-based diagnostics and therapeutics, particularly in cancer and inflammatory diseases. His recent publications highlight interdisciplinary studies linking carbohydrate metabolism to p53 tumor suppression pathways and RNA-binding protein regulation in cancer. Awards include AAAS Fellow (2015), ACS Isbell Award (2012), and NSF CAREER Award (2006). He earned his Ph.D. at Wayne State University (2000) and B.S. at Xiamen University (1994). Scientific Awards American Association for the Advancement of Science Fellow (2015) Dean's Team Award for Excellence (2013) Carbohydrate Research Award for Creativity (2013) ACS CARB Horace S. Isbell Award (2012)

Audrey LambView profile

Professor

• Mechanistic enzymology
• Metabolic pathways
• Structural biology
• +4 more

Dr. Audrey Lamb is a Professor and Chair of the Department of Chemistry at The University of Texas at San Antonio (UTSA), within the College of Sciences. She joined UTSA in 2020 after rising to full professor at the University of Kansas, where she served as interim dean of graduate studies in 2019. Her leadership extends to professional organizations, including serving as an elected council member for the American Society for Biochemistry and Molecular Biology. Dr. Lamb received her B.S. in Chemistry from Furman University in 1993 and her Ph.D. in Biochemistry from Vanderbilt University School of Medicine in 1998. She completed postdoctoral studies in biochemistry at Northwestern University before beginning her academic career at the University of Kansas in 2003. Dr. Lamb's research focuses on understanding bacterial pathogenesis through mechanistic enzymology and structural biology. Her lab investigates how human pathogens biosynthesize metallophores for metal ion scavenging and riboflavin (Vitamin B2) biosynthesis pathways. These studies aim to identify targets for novel antibiotic development against multidrug-resistant pathogens. Her work spans bacterial enzymology, structural biology, and metabolic pathway analysis, with applications in antimicrobial drug design. Analysis of Dr. Lamb's recent publications reveals a consistent focus on enzyme mechanisms in bacterial metabolism, particularly in metallophore and riboflavin biosynthesis pathways. Her work combines structural biology with kinetic analysis to elucidate catalytic mechanisms. Many publications investigate enzymes from pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and Trypanosoma cruzi, highlighting the translational potential of her basic science research for antimicrobial development. Dr. Lamb has received notable recognition including: Election as a 2022 Fellow of the American Association for the Advancement of Science (AAAS) Award-winning teaching and mentoring at undergraduate and graduate levels Dr. Lamb has mentored numerous students and postdoctoral fellows, with many alumni now in academic, industrial, and research positions. Her lab has received funding from prestigious sources including the National Institutes of Health, National Science Foundation, American Lung Association, and W.M. Keck Foundation. She actively collaborates with researchers at Loyola University Chicago, Texas A&M University, University of Kansas Medical Center, and UTSA's Department of Molecular Microbiology and Immunology. The Lamb Lab maintains a comprehensive suite of equipment for protein biochemistry and structural studies, including multiple AKTA FPLCs, a stopped-flow spectrophotometer, crystallization robot, various spectrophotometers, and HPLCs. This infrastructure supports their research on enzyme mechanisms and structural biology of bacterial metabolic pathways.